EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of PD ‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study

Bolun Zhao, Mengyu Zhang, Jingyi Tang, Daopei Zou, Fang Liu, Qiong Shi, Tianwen Gao, Chunying Li iD, Guannan Zhu iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Bolun Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Melanoma, Indoles, Quinolines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune‐checkpoint inhibitors are now used more commonly in combination than monotherapy as the first‐line choice in patients with unresectable advanced melanoma. Nevertheless, for cases that progressed after the initial combination therapy, the subsequent regimen option can be very difficult. Herein, we reported the efficacy and safety of a triple combination regimen in Chinese unresectable advanced melanoma patients who had poor responses to the first‐line immune therapy.

Methods

We reviewed the clinical profiles of patients diagnosed with stage IIIC‐IV melanoma between June 1, 2020, and September 30, 2023. The patients who failed the prior immune therapies and received anti‐PD‐1 mono antibody plus interferon(IFN)‐alpha 1b and anlotinib hydrochloride as the second‐line therapy were enrolled in the retrospective analysis. Additionally, we examined the exhaustion of T‐cells using mIHC staining in available tumor samples.

Results

Fifty‐five patients were included in this study. The median follow‐up period was 13.6 months. The objective response rate evaluated by the investigators was 9.1%(1CR, 4PR). The disease control rate was 47.3%. The median overall survival was 17.6 months, and the median progression‐free survival was 2.8 months. The adverse events rate of any grade was 100%. Grade 3 or 4 irAEs were observed in 29.1% of cases. Multiplex immunohistochemical staining revealed an increased trend of TIM3 expression on tumor‐infiltrating T cells in patients without objective response.

Conclusion

PD‐1 monoclonal antibody plus interferon‐alpha 1b plus anlotinib showed acceptable tolerability and anticancer benefits in Chinese metastatic melanoma patients as a second‐line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaIndolesQuinolinesAntineoplastic Combined Chemotherapy ProtocolsProgrammed Cell Death 1 ReceptorHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultImmune Checkpoint InhibitorsInterferon-alphaNeoplasm StagingTreatment Outcome

Stichwörter der Autor:innen

IFN‐α1bPD‐1advanced melanomaanlotinibsecond‐line therapy

Substanzen

anlotinibIndolesQuinolinesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsInterferon-alphaPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

ORCID-Profile: Chunying Li, Guannan Zhu

Förderung

  • the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, B., Zhang, M., Tang, J., Zou, D., Liu, F., Shi, Q., Gao, T., Li, C., & Zhu, G. (2024). Efficacy and safety of PD ‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study. Cancer Medicine. https://doi.org/10.1002/cam4.70087

Vancouver

Zhao B, Zhang M, Tang J, Zou D, Liu F, Shi Q, et al. Efficacy and safety of PD ‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study. Cancer Medicine. 2024. doi:10.1002/cam4.70087

BibTeX
@article{Zhao2024,
  author = {Zhao, Bolun and Zhang, Mengyu and Tang, Jingyi and Zou, Daopei and Liu, Fang and Shi, Qiong and Gao, Tianwen and Li, Chunying and Zhu, Guannan},
  title = {Efficacy and safety of PD ‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70087}
}
Kostenlos starten →